Johnson & Johnson (NYSE:JNJ) Shares Sold by Ledyard National Bank

Ledyard National Bank cut its position in Johnson & Johnson (NYSE:JNJ) by 1.6% during the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 54,183 shares of the company’s stock after selling 894 shares during the period. Ledyard National Bank’s holdings in Johnson & Johnson were worth $8,781,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other large investors also recently modified their holdings of JNJ. Innealta Capital LLC purchased a new stake in shares of Johnson & Johnson in the 2nd quarter valued at approximately $27,000. MFA Wealth Advisors LLC purchased a new position in shares of Johnson & Johnson in the 2nd quarter valued at $43,000. Fairfield Financial Advisors LTD purchased a new position in shares of Johnson & Johnson in the 2nd quarter valued at $46,000. Fairway Wealth LLC grew its position in shares of Johnson & Johnson by 217.1% in the 2nd quarter. Fairway Wealth LLC now owns 333 shares of the company’s stock valued at $49,000 after buying an additional 228 shares during the last quarter. Finally, Quarry LP purchased a new position in shares of Johnson & Johnson in the 2nd quarter valued at $49,000. 69.55% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Several research analysts have issued reports on JNJ shares. TD Securities lowered their price objective on shares of Johnson & Johnson from $195.00 to $185.00 in a research report on Thursday, July 18th. TD Cowen lowered their price objective on shares of Johnson & Johnson from $195.00 to $185.00 and set a “buy” rating on the stock in a research report on Thursday, July 18th. Royal Bank of Canada raised their price objective on shares of Johnson & Johnson from $178.00 to $181.00 and gave the stock an “outperform” rating in a research report on Wednesday, October 16th. The Goldman Sachs Group reduced their target price on shares of Johnson & Johnson from $160.00 to $155.00 and set a “neutral” rating for the company in a research note on Friday, July 19th. Finally, Morgan Stanley raised their target price on shares of Johnson & Johnson from $169.00 to $175.00 and gave the stock an “equal weight” rating in a research note on Wednesday, October 16th. Six analysts have rated the stock with a hold rating, seven have issued a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, Johnson & Johnson currently has an average rating of “Moderate Buy” and an average price target of $175.93.

Johnson & Johnson Stock Performance

Shares of NYSE JNJ opened at $162.85 on Tuesday. Johnson & Johnson has a 12 month low of $143.13 and a 12 month high of $168.85. The company has a 50-day simple moving average of $163.04 and a 200-day simple moving average of $154.77. The company has a market cap of $391.92 billion, a PE ratio of 10.15, a price-to-earnings-growth ratio of 2.65 and a beta of 0.52. The company has a debt-to-equity ratio of 0.44, a current ratio of 1.07 and a quick ratio of 0.85.

Johnson & Johnson (NYSE:JNJ) last posted its earnings results on Tuesday, October 15th. The company reported $2.42 EPS for the quarter, topping analysts’ consensus estimates of $2.21 by $0.21. Johnson & Johnson had a net margin of 46.34% and a return on equity of 36.60%. The business had revenue of $22.47 billion for the quarter, compared to analysts’ expectations of $22.17 billion. During the same period in the previous year, the company posted $2.66 earnings per share. The business’s revenue for the quarter was up 5.2% compared to the same quarter last year. On average, equities analysts anticipate that Johnson & Johnson will post 10 earnings per share for the current year.

Johnson & Johnson Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Tuesday, December 10th. Investors of record on Tuesday, November 26th will be issued a $1.24 dividend. The ex-dividend date is Tuesday, November 26th. This represents a $4.96 annualized dividend and a yield of 3.05%. Johnson & Johnson’s dividend payout ratio is presently 30.92%.

Insider Activity at Johnson & Johnson

In related news, VP Robert J. Decker sold 5,635 shares of the company’s stock in a transaction on Friday, August 30th. The shares were sold at an average price of $165.06, for a total value of $930,113.10. Following the sale, the vice president now directly owns 18,973 shares of the company’s stock, valued at $3,131,683.38. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. 0.16% of the stock is currently owned by corporate insiders.

Johnson & Johnson Company Profile

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.